Login to Your Account



Stock Takes 18% Hit Based on Confusion

Potential M&A Target Achillion Clarifies Positive HCV Data

By Karen Pihl-Carey
BioWorld Today Contributing Writer

Tuesday, April 24, 2012

Following a weekend poster presentation that confused some investors, Achillion Pharmaceuticals Inc. clarified on Monday that all patients who completed a 24-week regimen involving its hepatitis C virus (HCV) drug ACH-1625 had undetectable levels of HCV RNA – yet the company's stock continued a downward slide throughout the day.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription